Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Alpine Immune Sciences advances drug pipeline amidst financial challenges

Alpine Immune Sciences shows promise with progress on povetacicept and strategic studies for autoimmune diseases.
While facing financial challenges, the company's strong cash position and collaborations offer growth opportunities.
Effective cost management, successful clinical trials, and market expansion are crucial for Alpine's future success.

Alpine Immune Sciences reports robust 2023 performance and clinical advancements

Alpine Immune Sciences demonstrated strong financial performance and promising clinical advancements in 2023.
The company's focus on povetacicept as a disease-modifying therapy presents significant opportunities for growth.
Challenges lie in maintaining clinical momentum and managing expenses effectively to sustain progress.
Overall, Alpine's strategic initiatives position it well for continued success in the biopharmaceutical space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. Thursday, March 28th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company.

Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Alpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This compares to loss of $0.41 per share a year ago.

Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates

Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023. “2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-cla.

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Alpine Immune Sciences (ALPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?

Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Inf.

Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences. Monday, March 4th, Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer will participate in an IgA Nephropathy corporate panel at 9:10 am ET/6:10 am PT during the TD Cowen 44th Annual Health.

Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Alpine Immune Sciences, Inc. stock has increased by 176% since early coverage, driven by positive data from the basket study RUBY-3. Low-dose povetacicept showed meaningful improvements in disease biomarkers for IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company plans to advance povetacicept in a pivotal trial for IgA nephropathy and start a phase 2 study for systemic lupus erythematosus.

Alpine Immune Looks Highly Interesting Except For The Price (Rating Upgrade)

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company has amended the previously announced 2020 option and license agreement with AbbVie for acazicolcept. Key terms of the amended agreement: Company will stop enrollment under the amended agreement in the phase 2 study of acazicolcept in systemic lupus erythematosus.

Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie

Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.

Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that Mitchell Gold, M.D., Executive Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30 am PT/10:30 am ET, and the Company will participate in one-on-one investor meetings. A live webcast.

Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Aurinia Pharmaceuticals

Journey Medical Corp

Harpoon Therapeutics Inc

Lyra Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High?

Here is how Alpine Immune Sciences, Inc. (ALPN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the upcoming Evercore ISI HealthconX Conference, November 28-30, 2023. Thursday, November 30th, the Company will participate in a fireside chat at 7:55 am ET/4:55 am PT and also host investor meetings. A live webcast of the fireside chat will.

Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 79.4% in Alpine Immune Sciences, Inc. (ALPN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023. Povetacicept Presentation Highlights Include: In SLE patients, BAFF- and APRIL-rela.

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023. “The first presentation of clinical data in patients for povetacicept during a late-breaking session at the American Society of Nephrology (ASN) Kidney Week Meeting marked an important milest.

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023. Acazicolcept Presentation Highlights Include: Acazicolcept target-related genes (IC.

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. The sha.

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an addition.

Alpine Immune Sciences Announces Proposed Public Offering

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona. In addition, the Company presented safety, tolerability, pharma.

Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company today presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking poster session at the American Society of Nephrology (ASN) Kidney Week in Philadelphia, Pennsylvania. In addition, the Company plans to host an investor eve.

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Alpine Immune Sciences Stock (ALPN)